Aquatic Capital Management LLC Sells 15,898 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Aquatic Capital Management LLC trimmed its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 40.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,102 shares of the medical device company's stock after selling 15,898 shares during the period. Aquatic Capital Management LLC's holdings in AtriCure were worth $706,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of ATRC. Blue Trust Inc. lifted its holdings in shares of AtriCure by 1.8% during the 4th quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company's stock valued at $414,000 after purchasing an additional 265 shares in the last quarter. Invesco Ltd. grew its position in AtriCure by 0.8% during the fourth quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock worth $1,334,000 after buying an additional 334 shares in the last quarter. Perkins Capital Management Inc. boosted its stake in shares of AtriCure by 1.3% in the 4th quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company's stock valued at $927,000 after purchasing an additional 400 shares in the last quarter. Truist Financial Corp increased its holdings in shares of AtriCure by 2.6% during the fourth quarter. Truist Financial Corp now owns 15,717 shares of the medical device company's stock worth $480,000 after buying an additional 403 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of AtriCure by 0.9% in the 3rd quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company's stock valued at $1,569,000 after acquiring an additional 484 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company's stock.

Insider Activity

In other AtriCure news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the transaction, the director now directly owns 17,828 shares of the company's stock, valued at $679,603.36. This trade represents a 25.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 3.50% of the company's stock.

AtriCure Stock Down 0.1 %

NASDAQ:ATRC traded down $0.04 during mid-day trading on Wednesday, hitting $29.82. 65,423 shares of the company's stock were exchanged, compared to its average volume of 652,409. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The business has a fifty day moving average price of $33.18 and a 200 day moving average price of $34.73. AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.11. The company has a market cap of $1.48 billion, a PE ratio of -31.38 and a beta of 1.57.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.11. The firm had revenue of $123.62 million during the quarter, compared to analysts' expectations of $122.92 million. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The firm's quarterly revenue was up 13.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.28) earnings per share. Equities analysts predict that AtriCure, Inc. will post -0.6 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ATRC shares. Oppenheimer increased their target price on AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a research report on Thursday, February 13th. BTIG Research restated a "buy" rating on shares of AtriCure in a research report on Thursday, March 27th. Piper Sandler raised their price objective on AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Stifel Nicolaus lifted their price objective on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Finally, JMP Securities restated a "market outperform" rating and set a $60.00 price objective on shares of AtriCure in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $50.67.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.